These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 39032318)

  • 1. Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study.
    Colaneri M; Matone M; Fassio F; Lai A; Bergna A; Ventura CD; Galli L; Scaglione G; Gori A; Schiavini M
    Diagn Microbiol Infect Dis; 2024 Oct; 110(2):116452. PubMed ID: 39032318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
    Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 11. Early combination therapy of COVID-19 in high-risk patients.
    Orth HM; Flasshove C; Berger M; Hattenhauer T; Biederbick KD; Mispelbaum R; Klein U; Stemler J; Fisahn M; Doleschall AD; Baermann BN; Koenigshausen E; Tselikmann O; Killer A; de Angelis C; Gliga S; Stegbauer J; Spuck N; Silling G; Rockstroh JK; Strassburg CP; Brossart P; Panse JP; Jensen BO; Luedde T; Boesecke C; Heine A; Cornely OA; Monin MB
    Infection; 2024 Jun; 52(3):877-889. PubMed ID: 38017344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2.
    de Michelena P; Olea B; Torres I; González-Candelas F; Navarro D
    J Med Virol; 2022 Dec; 94(12):5836-5840. PubMed ID: 35986484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study.
    Bertuccio P; Degli Antoni M; Minisci D; Amadasi S; Castelli F; Odone A; Quiros-Roldan E
    Infection; 2023 Dec; 51(6):1633-1644. PubMed ID: 37024626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.
    Russo A; Grimaldi P; Pisaturo M; Onorato L; Coppola N
    Front Immunol; 2024; 15():1295029. PubMed ID: 38352882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience.
    Perrotta N; Angelo Fiorito L; Leanza C; Di Bari S; Casini G; Gentile R; Vescovo R; Piciocchi A; Ajassa C; Iaiani G; Maria Proli E; Russo G
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113101. PubMed ID: 39265354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.
    Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y
    BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
    Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.